Developing effective therapies against multiple myeloma (MM) is an unresolved challenge. Phosphatidylinositol-3-kinase (PI3K) activation may be associated with tumor progression and drug resistance, and inhibiting PI3K can induce apoptosis in MM cells. Thus, targeting of PI3K is predicted to increase the susceptibility of MM to anticancer therapy. The lead compound of a novel class of PI3K inhibitors, BAY80-6946 (IC 50 ¼ 0.5 nM against PI3K-a), was highly efficacious in four different MM cell lines, where it induced significant antitumoral effects in a dose-dependent manner. The compound inhibited cell cycle progression and increased apoptosis (Po0.001 compared with controls). Moreover, it abrogated the stimulation conferred by insulin-like growth-factor-1, a mechanism relevant for MM progression. These cellular effects were paralleled by decreased Akt phosphorylation, the main downstream target of PI3K. Likewise, profound antitumoral activity was observed ex vivo, as BAY80-6946 significantly inhibited proliferation of freshly isolated myeloma cells from three patients (Po0.001 compared with vehicle). In addition, BAY80-6946 showed convincing in vivo activity against the human AMO-1 and MOLP-8 myeloma cell lines in a preclinical murine xenograft model, where treatment with 6 mg/kg every other day for 2 weeks reduced the cell numbers by 87.0% and 69.3%, respectively (Po0.001 compared with vehicle), without overt toxicity in treated animals.
INTRODUCTION
Overcoming chemoresistance is arguably the most important challenge in today's cancer therapy. Multiple myeloma (MM), a common hematological malignancy arising from clonal expansion of malignant plasma cells, vividly highlights this notion. 1 Despite numerous therapeutic approaches, including high-dose chemotherapy, stem cell transplantation and several innovative compounds or combinations of the above, MM still remains an incurable condition. [2] [3] [4] [5] Drug resistance usually leads to the fatal outcome. 6 Myeloma cells can exhibit several constitutive or acquired mechanisms of drug resistance, some of which even may be facilitated by chemotherapeutic treatment, such as multidrug resistance gene or P-glycoprotein upregulation. 7 In addition, myeloma cell binding to fibronectin can lead to cell adhesionmediated drug resistance, and various cytokines including insulinlike growth factor type 1 (IGF-1), interleukin-6, vascular endothelial growth factor and tumor necrosis factora can trigger signaling pathways, supporting proliferation and reducing apoptosis of myeloma cells. [8] [9] [10] [11] [12] [13] IGF-1 is of particular importance, as it activates PI3K (phosphatidyl inositol 3-kinase)/Akt signaling, a prototypic survival pathway involved in proliferation, anti-apoptosis, cell invasiveness, angiogenesis and drug efflux in tumors. 14 The PI3K family comprises lipid kinases, whose activation generates PI phosphates, mainly PI3, 4P2 (PIP 2 ) and PI3, 4,5P3 (PIP 3 ). 15 PIP 3 functions as a second messenger, which activates multiple downstream targets. The main downstream target of class IA PI3 kinases is Akt, which is recruited to the inner plasma membrane where it becomes phosphorylated on amino acid residues Thr308 and Ser473. 16 Akt then leads to activation of downstream substrates involved in cell cycle regulation and apoptosis prevention. 16 Akt is directly responsible for the phosphorylation of several components of the cell-death machinery. The latter includes the pro-apoptotic proteins Bad, caspase 9 and FKHR, a member of the Forkhead family of transcription factors, which leads to inhibition of Bim and Fas ligands. 17, 18 In addition, Akt is indirectly involved in the regulation of two central modulators of cell death, namely nuclear factor-kappa B (NF-kB) and p53, and it causes cell cycle progression by inhibition of glycogen synthase kinase-3, which inhibits expression of cyclin D1. 16 The PI3K/Akt pathway is constitutively active in many malignancies including MM, breast cancer, ovarian cancer, melanoma, acute myelogenous leukemia and gastric carcinomas. 19 Akt activation in tumors may be caused by loss of tumor suppressor phosphatase and tensin homolog deleted on chromosome ten (PTEN) function, amplification or mutation of PI3K or growth factor receptors. [20] [21] [22] All of them are associated with poor prognosis. 23 Blocking of PKC, a treatment that results in Akt inhibition, abrogates tumor growth in some xenograft mouse models, and PKC is a promising therapeutic target in acute myelogenous leukemia and MM. 24 Given the pivotal role of the PI3K/Akt pathway in tumor biology and promising results of Akt inhibition in experimental tumor therapy, 25 we have investigated the novel highly selective PI3K inhibitor BAY 80-6946 in four different human myeloma cell lines, as well as in freshly isolated myeloma cells from three patients. 1 We demonstrated a profound impact of this compound on Akt phosphorylation, apoptosis induction and reduction of tumor growth in vitro and, using two representative myeloma lines, in a preclinical xenograft model in vivo.
MATERIALS AND METHODS

Cell culture and reagents
The human MM cell lines AMO-1, 26 KMS-12-BM, 27 MOLP-8 28 and U-266 29 were cultured at 37 1C in a 5% CO 2 -humidified atmosphere in RPMI 1640 medium supplemented with 10-20% fetal calf serum (FCS), 100 U/ml penicillin and 100 mg/ml streptomycin (PAA Laboratories, Pasching, Austria). All cell cultures were routinely checked for the absence of mycoplasma infection. A 100 mM stock solution of BAY 80-6946 was prepared in vehicle solution (5 mM trifluoroacetic acid in dimethyl sulfoxide). Aliquots were stored at À 20 1C. For stimulation with recombinant IGF-1 (ImmunoTools, Friesoythe, Germany), the cells were cultured at 37 1C in RPMI 1640 serum-free culture medium with or without BAY 80-6946 for 16 h, followed by incubation with 100 ng/ml of IGF-1 for 20 min. Vehicle-treated cells served as controls.
Isolation of primary human myeloma cells
The experiments with human cells were approved by the local ethics committee of the University Medical Center Gö ttingen (protocol 13/3/13). All patients gave their informed consent. Heparinized blood samples in 50 ml tubes were subjected to density gradient centrifugation without brake for 20 min at a centrifugal force of 600 g using 10 ml Ficoll as the separating phase. The buffy coat containing peripheral blood mononuclear cells was transferred into a fresh tube and washed with PBS. Myeloma cells were isolated by magnetic cell sorting using CD138 MicroBeads (MACS, Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions. Samples with a high amount of CD138 þ cells were used for proliferation assays.
Preparation of cell extracts and western blot analysis
Cultured human myeloma cells were washed twice with PBS (PAA Laboratories) and solubilized on ice in lysis buffer (100 ml, 1 M Tris, pH 7.0; 200 ml, 10% SDS; 100 ml b-mercaptoethanol; 1314.3 ml dH 2 0, supplemented with 285.7 ml of Complete Protease Inhibitor (Roche Diagnostics, Indianapolis, IN, USA). The protein concentrations in the lysates were determined by Bradford assays (Bio-Rad, Munich, Germany). Equal amounts of protein were separated by SDS-PAGE and transferred onto nitrocellulose membranes. The membranes were incubated with primary antibodies overnight followed by horseradish peroxidase-labeled mouse anti-rabbit immunoglobulin G (IgG) and a chemiluminescence reagent (ECL solution in an equal mix of solution 1 (9 ml dH 2 O, 1 ml 1 M Tris-HCl, pH 8.5, 45 ml coumaric acid and 100 ml Luminol) and solution 2 (9 ml dH 2 O, 1 ml 1 M Tris-HCl, pH 8.5, and 6 ml H 2 O 2 , 30%)). Phospho-Akt was detected using the Western Breeze chemiluminescent immunodetection system as described in the manual (Invitrogen, Carlsbad, CA, USA). Antihuman actin, clone C4 (Millipore, Temecula, CA, USA), was used at a 1:10 000 dilution, anti-human Akt (Cell Signaling Technology, Danvers, MA, USA) was used at a 1:2000 dilution and anti-human phospho-Akt (Ser473; Cell Signaling Technology) was used at a 1:500 dilution. Anti-PI3 kinases p110a, p110b and p110g (Cell Signaling Technology) was used at a 1:1000 dilution and anti-PI3 kinase p110d (Santa Cruz Biotechnology, Heidelberg, Germany) was used at a 1:100 dilution. 
Cell cycle analysis
Cell cycle analysis was performed by flow cytometry. After 4, 12 and 24 h of culture with BAY 80-6946 or vehicle, the cells were fixed in 70% ice-cold ethanol, washed twice, resuspended in 500 ml cold PBS containing 50 mg/ ml propidium iodide and 0.1 mg/ml RNase A (Roth, Karlsruhe, Germany). Cells were incubated at room temperature for 30 min. Thereafter, the cells were analyzed using a fluorescence activated cell sorter Canto II (Becton Dickinson).
Myeloma xenograft mouse model
Mouse experiments were approved by the appropriate authorities (Niedersächsisches Landesamt fü r Verbraucherschutz und Lebensmittelsicherheit, protocol 33.9.42502-04/099/09). Nude mice (NU/J Foxn1 nu ) were kept in a climate-controlled specific pathogen-free facility of the University Medical Center Gö ttingen. To evaluate experiments, mice were anaesthetized by isoflurane inhalation and killed by cervical dislocation according to the international guidelines. Age and sex-matched mice were injected into the peritoneum with 5 Â 10 6 human myeloma cells of the cell lines MOLP-8 (n ¼ 5 vehicle control mice and n ¼ 5 BAY 80-6946-treated mice) or AMO-1 (n ¼ 4 vehicle control mice and n ¼ 4 BAY 80-6946-treated mice), respectively. Treatments were started 1 day after myeloma cell injection. Treatment regimens were as follows: control mice received i.p. vehicle injections (positive controls), whereas BAY 80-6946-treated mice received i.p. injections of BAY 80-6946 at a dose of 6 mg per kilogram body weight each Monday, Wednesday and Friday for 2 weeks (altogether six injections per mouse). Untreated mice served as negative controls (no myeloma cell injection or treatment). Mice were killed after 2 weeks. Immediately after death, a thorough peritoneal lavage with PBS was performed, the mixed cell suspension obtained by this procedure was stored on ice and the total cell number (containing human myeloma and murine cells) was determined. Human myeloma cells were then identified by fluorescence activated cell sorter analysis. Cells were washed twice, and one sample was stained with anti-human CD138 (Becton Dickinson; 20 ml per test) and another sample was stained with anti-human HLA (human leukocyte antigen)-ABC (Becton Dickinson; 10 ml per test). Isotype-matched PI3K inhibitor is effective against human MM J Glauer et al control IgG (Becton Dickinson) served as negative control. After the peritoneal lavage, mice were dissected and a piece of each of the following organs was fixed in paraffin, whereas another piece was frozen in liquid nitrogen: spleen, liver, lung, femur, abdominal lymph node and peritoneum. To identify the potential presence of spread tumor cells, spleen cells and bone-marrow cells isolated by rinse cytology were stained with anti-human CD138 and anti-human HLA-ABC and analyzed by flow cytometry. The experiment was performed twice with similar results.
Statistical analysis
Statistical analyses were performed using the GraphPad Prism V5.00 software (GraphPad Software, San Diego, CA, USA). P-values of fluorescence activated cell sorter analyses, proliferation and apoptosis experiments were evaluated using one-way analysis of variance followed by Bonferroni post hoc test. P-values of in vivo experiments were analyzed using the two-tailed t-test. P-values of o0.05 (confidence interval of 95%) were considered statistically significant. Significance levels are given as * when Po0.05, ** when Po0.01 and *** when Po0.001, respectively. All data are represented as mean±s.d.
RESULTS
Differential expression of PI3K isoforms and varying levels of constitutive or IGF-1-induced activation of Akt in human myeloma cells Activation of the PI3K/Akt pathway has been implicated in progression and drug resistance of human MM. 25 Indeed, Akt is constitutively active in many types of cancer including MM, but not in nonmalignant hematopoietic cells from the same patients. [30] [31] [32] [33] However, the levels of constitutive Akt activation may vary widely. Examination of PI3K expression levels by western blot analysis revealed marked constitutive expression of the Given that IGF-1 may activate Akt and is a critical growth factor in MM especially in the context of drug resistance, 13, 14 we also analyzed IGF-1-stimulated levels of Akt activation in myeloma cells. Stimulation by IGF-1 at a concentration of 100 ng/ml increased the level of phosphorylated Akt in all cell lines. Of note, stimulation of AMO-1 or MOLP-8 cells led to a sharp increase, whereas KMS-12-BM cells only showed a weak response to IGF-1 stimulation (Figure 1b) . Flow cytometry analysis was performed as a second independent method and confirmed the results obtained by western blot (Figure 1c ). Based on these results, the two cell lines AMO-1 and MOLP-8 showing moderate constitutive and the highest difference between constitutive and induced Akt activation were selected for further functional studies.
BAY 80-6946 is a potent and selective PI3K inhibitor that blocks Akt activation in human myeloma cells To identify small-molecule compounds that interfered specifically with PI3K and the activation of Akt in human tumor cells, compounds were tested in a large-scale high throughput screening for their ability to inhibit PI3K isoforms. 34 BAY 80-6946 (7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo [1,2-c]quinazolin-5-amine), a small-molecule compound of M r 359.42 ( Figure 2) showed the desired activity: it specifically inhibited several recombinant human PI3K isoforms, with the strongest activity toward PI3K-a (IC 50 ¼ 0.5 nM), followed by PI3K-d (IC 50 ¼ 0.7 nM), PI3K-b (IC 50 ¼ 3.7 nM) and PI3K-g (IC 50 ¼ 6.4 nM; Figure 2 ). The selectivity of the compound was confirmed using a panel of 219 additional cell-free enzyme assays including various other kinases, phosphatases, phospholipases and proteases. There was no inhibitory activity toward any of these enzymes up to a concentration of 1000 nM (Supplementary Table 1) , including other kinases of the PI3K/Akt pathway such as PDK-1 and the three Akt isoforms themselves. The only exception was a moderate activity against mTOR (mammalian target of rapamycin), which was lower than that against the PI3K isoforms by one order of magnitude (IC 50 ¼ 45 nM; Figure 2 ). These results clearly indicated that BAY 80-6946 is a highly selective inhibitor of PI3K.
When the impact of different concentrations of BAY 80-6946 (10 nM, 50 nM and 100 nM) against constitutively phosphorylated Akt was assessed on the protein level by flow cytometry, a significant dose-dependent inhibition of Akt activation by up to 50% could be observed in all cell lines examined (cell lines AMO-1 and MOLP-8 depicted in Figure 3a , and KMS-12-BM and U-266 depicted in Supplementary Figure S1a) . Indeed, in both AMO-1 and MOLP-8 cells, highly significant inhibition of constitutive Akt phosphorylation (Po0.001 compared with vehicletreated controls) was observed at concentrations of as low as 10 nM (Figure 3a) . In U-266 and KMS-12-BM cells, inhibition of Akt phosphorylation appeared to be somewhat weaker (Supplementary Figure S1a) .
Given that IGF-1 led to a marked increase of phosphorylated Akt, two myeloma cell lines (AMO-1 and MOLP-8) were exposed to BAY 80-6946 for 16 h and then stimulated by IGF-1 at 100 ng/ml for 20 min. As detected by flow cytometry analysis, the IGF-1-induced increase of Akt phosphorylation was completely abrogated by BAY 80-6946 and was comparable to levels seen in non-stimulated cells (Figure 3b ). Western blot analysis used as a second method confirmed the dramatic downregulation of IGF-1-stimulated p-Akt by BAY 80-6046, even at concentrations of as low as 10 nM (Figure 3c) . Thus, BAY 80-6946 is a potent PI3K inhibitor in human myeloma cells, which can even overcome stimulatory effects of IGF-1.
Induction of apoptosis, inhibition of proliferation and cell cycle regulation in human myeloma cells through PI3K inhibition by BAY 80-6946 Akt is directly responsible for the phosphorylation of several components of the cell-death machinery such as Bad, 35 caspase 9 17 or FKHR, 18 and it is involved indirectly in the regulation of two central modulators of cell fate, NF-kB and p53. 17, 36 Therefore, it was reasonable to assume that inhibition of Akt activation by BAY 80-6946 would increase apoptosis and reduce proliferation of myeloma cells.
When the generation of histone-bound DNA fragments was used as a parameter to measure apoptotic responses of human myeloma cells to the treatment with BAY 80-6946, a In addition to its pivotal role in the regulation of apoptosis, PI3K is involved in cell growth regulation. When myeloma cell viability was assessed in response to BAY 80-6946, a moderate, yet consistent and significant reduction was observed in all four myeloma lines in a dose-dependent manner. The viability in the cell lines AMO-1 and MOLP-8 was decreased by up to 30% at a concentration of 100 nM (Po0.001 compared with vehicle-treated cells; Figure 4b ), and this decrease was weakest in the U-266 line (Po0.01 only at 100 nM compared with vehicle-treated cells; Supplementary Figure S1c) .
The incorporation of BrdU as an indicator of proliferation was reduced likewise in BAY80-6946-treated myeloma cells. Notably, BAY 80-6946 inhibited the proliferation in IGF-1-stimulated myeloma cells in a dose-dependent manner. The strongest decrease was seen in AMO-1 cells, in which proliferation was reduced by 35% at a concentration of 50 nM and by 50% at a concentration of 100 nM (Po0.01 compared with vehicle control; Figure 4c ).
To test whether BAY 80-6946 would exert its inhibitory activity against 'natural' tumor cells as well, we isolated myeloma cells from three patients with a high tumor burden. Indeed, treatment of these freshly isolated CD138 þ myeloma cells with BAY 80-6946 resulted in significant inhibition of proliferation in a dosedependent manner (Figure 4d ). Significant inhibition of proliferation was detected at concentrations of as low as 50 nM, and proliferation was reduced by B50% when BAY 80-6946 was used at a concentration of 1 mM (Po0.001 compared with vehicletreated cells; Figure 4d ).
The marked apoptosis induction and the growth inhibition by Bay 80-6946 were paralleled by a conspicuous modulation of the cell cycle in myeloma cells. The rationale for these investigations was that the PI3K/Akt pathway profoundly influences cell cycle regulation inasmuch as activation of PI3K phosphorylates and thus inhibits the glycogen synthase kinase-3 protein, which negatively regulates the expression of cyclin D1. 40 Increased cyclin D1 expression facilitates the transition from G0/G1 to S phase. 48 Thus, it was conceivable that higher cell numbers would remain in the G0/G1 phase after treatment with BAY 80-6946.
To test the latter hypothesis, the cell cycle phases of two myeloma cell lines, AMO-1 and MOLP-8, were analyzed by flow cytometry. Indeed, a dose-dependent increase of cells in the GO/G1 phase and, conversely, a decrease of cells in the S phase were detected after exposure of the myeloma cells to BAY 80-6946 ( Figure 5 ). After 24 h of treatment with BAY 80-6946 (100 nM), the cell number in the GO/G1 phase increased from 51 to 65% in AMO-1 cultures and from 53 to 68% in MOLP-8 cultures, respectively. Reciprocally, cells in the S phase decreased from 35 to 19% in AMO-1 cultures and from 34 to 20% in MOLP-8 cultures, respectively ( Figure 5 ). Lower concentrations of BAY 80-6946 (10 or 50 nM) showed similar, albeit less pronounced shifts in the same direction indicating dose dependency ( Figure 5) . Thus, it appears that the mutually synergistic activities of BAY 80-6946 on the cellular level, namely cell cycle arrest, and decreased proliferation on the one hand and apoptosis induction on the other, mount up to the net antitumoral activity exerted on myeloma cells in vitro.
Growth of human myeloma cells in vivo and therapeutic effect of BAY 80-6946 Given that no truly reliable preclinical animal model for human myeloma is available, we have used a murine xenograft model system using athymic NU/J Foxn1 nu mice transplanted intraperitoneally (i.p.) with the human myeloma cells AMO-1 or MOLP-8 (5 Â 10 6 cells/mouse), respectively. Although this model, similar to others, does not reflect all aspects of human myeloma, it allows the study of systemic effects of antitumoral compounds in an in vivo setting. Human myeloma cells were detected by the expression of HLA-ABC and CD138 (Figure 6a ). This method worked reliably when cells derived from the peritoneal cavity were analyzed. In a complete workup, we also assessed myeloma cell spread to other organs such as bone marrow and spleen. Indeed, a small, yet consistent and reproducible number of human cells could be isolated from the spleens, thus allowing an estimation of the systemic spread of myeloma cells. In contrast, only small and varying numbers of human myeloma cells could be detected in the bone marrow, thus precluding a valid assessment of this anatomical site.
When myeloma-bearing mice were treated systemically for 2 weeks with BAY 80-6946 (i.p., three times/week, 6 mg per kg body weight), flow cytometry analysis of cells obtained by peritoneal lavage revealed a profound therapeutic effect of BAY 80-6946. Compared with vehicle-treated animals, BAY 80-6946 significantly reduced the peritoneal number of MOLP-8 cells by 69.3% and the respective number of AMO-1 cells by 87%, respectively (Po0.001 in both cases; Figure 6b ).
In addition, when the systemic spread of human myeloma cells to the spleen was assessed, it was found that BAY 80-6946 did not prevent the systemic spread altogether but significantly reduced the number of human myeloma cells in the spleens of transplanted mice (reduction by B30% with both cell lines; Po0.01 compared with vehicle-treated animals; Figure 6c ). Thus, even considering the undeniable limitations of this model, it appears that BAY 80-6946 can markedly reduce the overall myeloma tumor burden in vivo and effects a moderate reduction of splenic myeloma cells when administered systemically. DISCUSSION Activation (phosphorylation) of Akt in MM cells, a feature that is primarily effected through PI3K signaling, is associated with poor prognosis and reduced survival of affected patients. 23 In many instances, constitutive Akt activation in myeloma cells appears to be the result of PTEN deletion, amplification or mutation of PI3K or growth factor receptor activation, resulting in a relative resistance to apoptosis with serious consequences. 17, 21, 37 Indeed, triggered by various cytokines, the PI3/Akt pathway activation is one of the most important hallmark features of drug resistance in MM, primarily due to the prevention of apoptosis. 6, 38 Furthermore, MM cell migration induced by cytokines, such as vascular endothelial growth factor, depends on PI3K/Akt signaling, whereas it is thought to be independent of mitogen-activated protien kinase signaling. 39 In contrast, Akt activation was not detected in nonmalignant hematopoietic cells from the same patients. 31, 32 Thus, it appears that constitutive activation of Akt constitutes an important step in the pathogenic cascade of MM. This rationale formed the basis of our investigations using BAY 80-6946, the lead compound of a novel class of small-molecule antitumoral imidazolinoquinazoline compounds. In contrast to other compounds described previously as dual PI3K/mTOR inhibitors such as BEZ-235, 40 BAY 80-6946 is a selective inhibitor of PI3K, a PI3K inhibitor is effective against human MM J Glauer et al trait that may be advantageous when potential side effects are considered. Given that constitutive and IGF-1-induced activation of Akt appear to be a distinctive feature of myeloma cells, it is conceivable that the mode of action of the highly selective pan-class I PI3K inhibitor, BAY 80-6946, or related compounds will primarily affect tumor cells and not other cell types. However, this hypothesis needs to be tested in future large-scale experiments. Currently used therapeutics, such as thalidomide, bortezomib and lenalidomide, target both myeloma cells and the bone-marrow microenvironment. Although these therapeutic strategies have elicited significant initial responses, only 25-35% of patients with relapsed myeloma respond to these agents. 6, 41, 42 Furthermore, several investigations have revealed that treatment with dexamethasone, doxorubicin or bortezomib induces Akt activation and thus leads to myeloma cell resistance. 25, 43, 44 In this light, it is reasonable to assume that additional treatment with a compound that specifically targets PI3K/Akt signaling in myeloma cells will be a worthwhile addition to the current therapeutic armamentarium.
Our results are consistent with and extend several previous reports, demonstrating a pivotal role of PI3K/Akt signaling in the (patho)-biology of MM. Regarding the mode of action of BAY 80-6946, the following aspects, which are not mutually exclusive, can be delineated:
First, treatment with BAY 80-6946 at nontoxic doses led to a considerable induction of apoptosis, inhibition of cell cycle progression inasmuch as the G0/G1: S ratio was shifted toward G0/G1, and, albeit to a lesser extent, inhibition of proliferation as well. The profound pro-apoptotic activity of BAY 80-6946 is plausible, because the PI3K/Akt pathway has a great impact on numerous substrates involved in regulation of apoptosis. For instance, Akt is directly responsible for the activation of several components of the cell-death machinery, including Bad, the proapoptotic caspase 9 and FKHR (a transcription factor of the forkhead family). 17, 18 Furthermore, Akt is indirectly involved in the regulation of NF-kB and p53. 17, 18, 35, 38 Although the decrease of Akt phosphorylation and the increase of apoptosis were seen in all four myeloma lines studied, the anti-viability activity of BAY 80-6946 against U-266 cells appeared to be less pronounced compared with the AMO-1, KMS-12-BM and MOLP-8 cell lines, respectively. Although there is no obvious explanation for this apparent discrepancy, one may speculate that compensatory activation of other proliferation promoting pathways in U-266 cells may contribute to the somewhat differential responses of the human myeloma lines to BAY 80-6946. Of note, BAY 80-6946 significantly inhibited proliferation ex vivo of 'natural' myeloma cells isolated from three patients. In any case, it is reasonable to assume that the negative effects of BAY 80-6946 on myeloma proliferation and cell cycle regulation, as well as the induction of apoptosis, add up to a profound overall antitumoral activity, presumably with a predominant role of the pro-apoptotic activity. Given that the acquisition of (drug-induced) apoptosis deficiency is arguably the single most important trait conferring drug resistance in myeloma cells, 45 the activity of BAY 80-6946 may contribute to overcoming drug resistance.
Second, BAY 80-6946 even overcame the growth advantages conferred by IGF-1. IGF-1 is one of the most important growth factors within the bone marrow, protecting myeloma cells from glucocorticoid-induced apoptosis through activation of the PI3K/ Akt pathway. 13 There have been attempts to use the inhibition of IGF-1 receptors for anti-myeloma therapy. 11 It is worth noting that IGF-1 is not only secreted in the bone marrow, but is also synthesized in the liver and found throughout the circulation. 13 As a result, myeloma cells are constantly exposed to IGF-1 stimulation. Thus, this growth factor is a general promoter of systemic myeloma cell proliferation and survival, and antagonizing its biological effects is, therefore, predicted to aid antitumoral therapies at many sites of the body. In our study, IGF-1 failed to protect the myeloma cells against BAY 80-6946-induced inhibition of proliferation, indicating that BAY 80-6946 can overcome the protective effects of this cytokine.
Third, in parallel to the in vitro effects, BAY 80-6946 also showed convincing anti-myeloma activity in vivo in a murine xenograft model using human myeloma cells. Research into the pathophysiology of myeloma is largely hampered by the lack of an appropriate animal model. In most of the recent studies, myeloma cells were simply inoculated subcutaneously and the local tumor volume was monitored. 26, 46 On the one hand, the strength of such models is the ease to directly assess local tumor growth. On the other hand, such approaches are limited by difficulties to determine the overall tumor cell load (that is, the number of tumor cells within a potentially mixed infiltrate or nodule) as well as the distant spread of tumor cells. Most of the current models suffer from the lack of an accurate reflection of the relevant bonemarrow environment, although first attempts to design such new mouse models have been made. 47 In this less-than-optimal situation, we have developed an easy-to-use murine xenograft model in which human myeloma cells were transplanted i.p. into NU/J Foxn1 nu mice. Bearing in mind said limitations, our model is an approximation that reflects some, but not all aspects of human myeloma. Using a short-term treatment regimen including vehicle-treated controls, BAY 80-6946 dramatically reduced the total myeloma cell count by 87.0% when AMO-1 cells were grafted, and by 69.3% in the case of MOLP-8 cells. Of note, BAY 80-6946 could also reduce systemic tumor progression, as exemplified by our analysis of the spleens of the recipient animals. It is also conceivable that BAY 80-6946 prevented myeloma cells from spreading to the spleen. In any case, this notion may be of particular interest, as mechanisms of myeloma cell spread are not yet fully understood, although extramedullary manifestations occur regularly. 48 In conclusion, this study provides strong circumstantial evidence that the novel PI3K inhibitor, BAY 80-6946, carries the potential to impede the growth of MM in vivo and in vitro. We have primarily addressed its direct activity against myeloma cells themselves. However, within the complex ''natural'' environment in human patients, multiple interactions of myeloma cells within the bone marrow and other anatomical sites may trigger activation not only of PI3K/Akt, but also of MEK/ERK, JAK/STAT3, NF-kB or other signaling cascades. 45, 49 All of them may contribute to tumor cell survival, drug resistance and/or migration. 6 Thus, although the activity of BAY 80-6946 certainly will have to be explored in additional settings, such as rationale-based combinations with targeted and chemo therapeutics, our data provide the first experimental evidence that such future studies are a worthwhile path to pursue.
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